BIOTECH

Technology of creation of three-dimensional scaffolds for growing 3D cells.

Growing organs is a promising bioengineering technology that creates a variety of viable biological organs for humans.

Innovation:
Scaffolds are similar in size and structure to the extracellular matrix:

Better simulate three-dimensional environment in vivo (living organism) during in vitro (laboratory) studies;
Substances of the intercellular matrix create a microenvironment;
Perform support, transport and signal functions.

3D cellular bodies:

New standard in the field of Biomedical research;
Serve for growing organs;
Have great potential for development in bioengineering.

SOLUTION

Problems of absence of scaffolds that are similar in size and structure to extracellular matrix on the world market.

INNOVATION

Simulate three-dimensional environment in vivo (living organism) during in vitro (laboratory) studies.
Substances of the intercellular matrix and create a microenvironment, perform reference, transport and signaling functions.

CONSUMERS

Tissue engineering laboratories, bioengineering research centers;
Research laboratories and institutes on the subject of Oncology, 3D tissue modeling;
Regenerative medicine centers, hospitals and diagnostic сenters
Biotechnology and pharmaceutical industry.

ABOUT THE PROJECT

Scaffold technology:

Cultivation of cells on three-dimensional carrier substrates for the purpose of spatial formation of the future cell organ.

Growing organs is a promising bioengineering technology that creates a variety of viable biological organs for humans.

3D cellular bodies:

New standard in the field of Biomedical research;
Serve for growing organs;
Have great potential for development in bioengineering.

Problem to be solved:

No scaffolds on the world market that are similar in size and structure to the extracellular matrix.

Extracellular matrix is produced by cells and forms the basis of connective tissue. It provides optimal microenvironment conditions, chemical transport and mechanical support for cells;
Scaffolds that are currently available on the market, are produced using nanofibers obtained by electrospinning – have a minimum fiber diameter of 100-300 nm, limited by production technology and do not correspond to the dimension of the extracellular matrix;
The average cost of developing a new drug is about $1.5 billion in the time from the beginning of developing a new drug to market entry is 12-13 years. With such indicators, companies and investors are interested in using an innovative product-3D scaffolds.

Innovation:

Scaffolds that are similar in size and structure to the extracellular matrix.

better simulate three-dimensional environment in vivo (living organism) during in vitro (laboratory) studies;
substances of the intercellular matrix and create a microenvironment, perform reference, transport and signalling functions.

Potential consumers:

Tissue engineering laboratories, bioengineering research centers;
Research laboratories and institutes on the subject of Oncology, 3D tissue modeling;
Regenerative medicine centers, hospitals and diagnostic centers;
Biotechnology and pharmaceutical industry.

The technology allows mass production of scaffolds from a plastic gel-like solidifying material with a micro porous structure simulating the structure of the extracellular matrix, including collagen, chitosan, alginate, and gelatin.

Hydrogel, which is a part of the material, creates conditions close to in vivo conditions for cells. Hydrogel compensates for the primary absence of extracellular matrix and serves as a nutrient for cells, as well as facilitates cell adhesion.
Scaffold can have a mechanical strength comparable to the strength of the bone (for compounds intended to replace bone defects).
Scaffold forms a three-dimensional micro porous structure in which cells can be cultivated and allows to simulate an organ in vitro.
The technology will allow you to create scaffolds of any desired shape, the material will be suitable for 3D printing.